Skip to main content
Figure 7 | Stem Cell Research & Therapy

Figure 7

From: Therapeutic efficacy and biodistribution of allogeneic mesenchymal stem cells delivered by intrasplenic and intrapancreatic routes in streptozotocin-induced diabetic mice

Figure 7

Evaluation of in vivo ADMSC Luc+ distribution. (A) Bioluminescent imaging of a representative mouse following intrasplenic administration of luciferase-positive adipose tissue-derived mesenchymal stem cells (ADMSCsLuc+). Bioluminescent signal was detected in regions of the spleen and liver for up to 8 days. (B) Kinetics of ADMSCLuc+ survival estimated by bioluminescence quantification. The bioluminescent signal increased 24 hours after injection, followed by a continuous decrease until its complete extinction after 8 days (n = 5 mice). (C) Bioluminescent imaging of a representative mouse following intrapancreatic injection of ADMSCsLuc+. Bioluminescent signal was detected in the region of pancreas for up to 8 days. (D) Kinetics of ADMSCLuc+ survival estimated by bioluminescence quantification. Following injection, the number of ADMSCsLuc+ gradually decreased during 8 days, after which the bioluminescent signal was no longer detected (n = 5 mice). (E) Ex vivo bioluminescent imaging of the pancreas, liver and spleen 48 hours after ADMSCLuc+ injection. ADMSCsLuc+ injected through the splenic route occupied the spleen and liver but not the pancreas of diabetic mice. In contrast, most ADMSCsLuc+ injected via the intrapancreatic route remained within the pancreas, albeit relatively few cells were detected in the spleen. No ADMSCsLuc+ were detected in the liver after intrapancreatic injection. Negative control represents a diabetic mouse that did not receive ADMSCsLuc+.

Back to article page